Marco Quarta

Dr. Marco Quarta leads Rubedo Life Sciences, driving its mission to develop treatments for chronic age-related diseases and extend healthspan. Rubedo strategy is based on a platform to discover the pathological cells involved in the biological aging process, such as senescent-like cells, and to develop small molecules designed for selectively targeting those cells across multiple indications in the Rubedo pipeline.

As a scientist, he earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine.

He is backed by over 20 years of research with a track record of scientific publications in top tier journals and international patents. He also co-founded the biotech company WetWare Concepts and the rejuvenation company Turn Biotechnologies, based on his work conducted at Stanford University with colleague Dr. Sebastiano on transient epigenetic reprogramming.